Mymetics Corp (MYMX)

[bow-tie]

OXFORD, UK – 5 May 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. The project, which started in October 2019, received funding from the Bill & Melinda Gates Foundation.

LOOKS LIKE YOU GOT BEATEN OUT AGAIN MR. KEMPER'S AND MYMETICS!!

https://www.enesipharma.com/enesi-pharma-achieves-key-milestone-in-development-of-thermostable-solid-dose-live-vaccines-against-measles-and-rubella/